Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with active psoriatic arthritis. The study includes adalimumab treatment as an active reference arm.

Inclusion Criteria:Participant is ≥18 years of age;Participant has a confirmed diagnosis of PsA per the 2006 Classification criteria for Psoriatic Arthritis (CASPAR) with symptoms for ≥6 months prior to the Screening Visit;Participant has active disease (defined by a TJC68 of ≥3 and a SJC66 of ≥3);Participant has either current active PsO or a dermatologist confirmed history of PsO;Participant tests negative for rheumatoid factor (RF) at the Screening Visit;Participant tests negative for anti-cyclic citrullinated peptide (CCP) antibodies at the Screening Visit;Participant must be, in the opinion of the investigator, a suitable candidate for treatment with adalimumab per approved local product information.Exclusion Criteria:Participant with known hypersensitivity to sonelokimab or any of its excipients;Participant with known hypersensitivity to adalimumab or any of its excipients;Participant who has previously failed on anti-interleukin (IL)-17 therapy;Participant who has previously failed on anti-tumor necrosis factor alpha (TNFα) therapy;Participant who has had previous exposure to more than 2 biologic agents of any type to treat PsA prior to the Screening Visit;Participant who has a diagnosis of chronic inflammatory conditions other than PsO or PsA;Participant who has a diagnosis of arthritis mutilans